Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Paeds Vivasfetal-neonatal-and-perinatal

Paeds Vivas · fetal-neonatal-and-perinatal

Haemolytic disease of the fetus and newborn — branching viva

Viva on the IgG-mediated mechanism, anti-D prophylaxis, MCA-PSV surveillance, intrauterine transfusion, and the postnatal phototherapy-IVIG-exchange ladder.

branching clinical structured oral2 min readVerification in progress

Target exams

RACP DCEMRCPCH ClinicalRCPSC Pediatrics
On this page
Study tools

Target exams

RACP DCEMRCPCH ClinicalRCPSC Pediatrics
Prompt
A Rh-negative woman with anti-D antibody at 22 weeks is being counselled about fetal surveillance; the candidate must explain the mechanism, justify the MCA-PSV threshold, and outline the antenatal and postnatal management.

Branch 1 — Mechanism and prevention

The examiner opens: "Explain how this woman became sensitised and how it could have been prevented." A strong candidate traces the fetomaternal haemorrhage that exposed her to fetal RhD-positive cells, the maternal immune response producing anti-D IgG, and the fact that this crosses the placenta from about 16 weeks via the neonatal Fc receptor to bind and destroy fetal red cells. The prevention is antenatal and postnatal anti-D immunoglobulin to Rh-negative mothers, which suppresses sensitisation, and anti-D after any sensitising event such as a miscarriage — the Crowther Cochrane reviews established the evidence base. [1]

Paediatrics Fellowship Pro

Continue reading

You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship library.

Sign in to continueSee pricing
References5ShowHide
  1. [1]Crowther CA, Middleton P Anti-D administration in pregnancy for preventing Rhesus alloimmunisation. Cochrane Database Syst Rev, 2013.PMID 23450526
  2. [3]Mari G, Deter RL, Carpenter RL, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. N Engl J Med, 2000.PMID 10620643
  3. [4]Mari G, Norton ME, Stone J, Berghella V, Sciscione AC, Tate D, Schenone MH Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #8: the fetus at risk for anemia--diagnosis and management. Am J Obstet Gynecol, 2015.PMID 25824811
  4. [5]American Academy of Pediatrics Subcommittee on Hyperbilirubinemia Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics, 2004.PMID 15231951
  5. [8]Zwiers C, Scheffer-Rath ME, Lopriore E, de Haas M, Liley HG Immunoglobulin for alloimmune hemolytic disease in neonates. Cochrane Database Syst Rev, 2018.PMID 29551014
Paediatrics Fellowship Pro

$29/ monthor $279 / year

The complete Paediatrics Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousGestational age assessment and preterm classification — vivafetal-neonatal-and-perinatalNextHearing loss in high-risk neonates — structured oral (viva)fetal-neonatal-and-perinatal